{"id":"calcineurin-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Gingival hyperplasia"},{"rate":null,"effect":"Increased infection risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcineurin inhibitors bind to immunophilins (cyclophilin or FK-binding protein) and form a complex that inhibits calcineurin phosphatase activity. This prevents dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells), thereby suppressing IL-2 and other cytokine production essential for T cell proliferation and immune response.","oneSentence":"Calcineurin inhibitors block the phosphatase enzyme calcineurin, preventing T cell activation and proliferation by inhibiting the transcription of pro-inflammatory cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:36.964Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention"},{"name":"Autoimmune and inflammatory conditions (e.g., atopic dermatitis, psoriasis, rheumatoid arthritis)"}]},"trialDetails":[{"nctId":"NCT01659606","phase":"PHASE2","title":"Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2012-07","conditions":"Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome","enrollment":40},{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT05238155","phase":"","title":"Evaluation of the Impact of Reduced Immunosuppression","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2021-10-19","conditions":"Graft Vs Host Disease","enrollment":100},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT05492578","phase":"PHASE2, PHASE3","title":"Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials","status":"ENROLLING_BY_INVITATION","sponsor":"Sanofi","startDate":"2022-08-22","conditions":"Dermatitis Atopic","enrollment":1663},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT07204275","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-09-30","conditions":"Primary Membranous Nephropathy","enrollment":176},{"nctId":"NCT06305286","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-03-04","conditions":"Type 1 Diabetes Mellitus","enrollment":70},{"nctId":"NCT05894512","phase":"","title":"Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2023-06-01","conditions":"Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Membranous Nephropathy - THSD7A Induced","enrollment":44},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT04380740","phase":"PHASE2","title":"Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2022-03-30","conditions":"Graft Vs Host Disease","enrollment":160},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT05288855","phase":"PHASE3","title":"Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis","status":"TERMINATED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2023-10-10","conditions":"Adolescent Lupus Nephritis, Pediatric Lupus Nephritis","enrollment":9},{"nctId":"NCT05962788","phase":"PHASE3","title":"Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis","status":"TERMINATED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2024-03-28","conditions":"Adolescent Lupus Nephritis, Pediatric Lupus Nephritis","enrollment":4},{"nctId":"NCT04877288","phase":"PHASE3","title":"A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-21","conditions":"Renal Allograft Recipients","enrollment":102},{"nctId":"NCT05621759","phase":"PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-09-07","conditions":"Graft Vs Host Disease","enrollment":27},{"nctId":"NCT05704205","phase":"NA","title":"The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-02-22","conditions":"Atopic Dermatitis Eczema, Atopic Dermatitis","enrollment":316},{"nctId":"NCT05704738","phase":"PHASE3","title":"A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-04-20","conditions":"Atopic Dermatitis","enrollment":532},{"nctId":"NCT00133887","phase":"PHASE3","title":"TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2004-04","conditions":"Skin Cancer, Kidney Transplantation","enrollment":77},{"nctId":"NCT00799188","phase":"PHASE3","title":"CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-10","conditions":"Cardiac Transplantation, Skin Cancer","enrollment":175},{"nctId":"NCT01743131","phase":"PHASE2","title":"Abatacept as GVHD Prophylaxis Phase 2","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-02-01","conditions":"Graft vs Host Disease, Malignancy","enrollment":186},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":200},{"nctId":"NCT07091175","phase":"PHASE2","title":"Dupilumab Therapy in Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-11-27","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent","enrollment":66},{"nctId":"NCT06224348","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids","status":"COMPLETED","sponsor":"Sanofi","startDate":"2024-01-18","conditions":"Dermatitis Atopic","enrollment":643},{"nctId":"NCT07252050","phase":"PHASE1, PHASE2","title":"Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-01-01","conditions":"Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant","enrollment":24},{"nctId":"NCT05724199","phase":"PHASE3","title":"A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-02-21","conditions":"Atopic Dermatitis","enrollment":746},{"nctId":"NCT07240389","phase":"NA","title":"Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.","status":"NOT_YET_RECRUITING","sponsor":"Milosz Pietrus","startDate":"2025-12-01","conditions":"Vulvar Lichen Sclerosus","enrollment":45},{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":"Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients","enrollment":212},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT03680092","phase":"PHASE2","title":"Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation","status":"COMPLETED","sponsor":"Dimitrios Tzachanis, MD PhD","startDate":"2019-11-26","conditions":"GVHD, Hematologic Neoplasms","enrollment":43},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT06478017","phase":"PHASE2","title":"Belatacept in Heart Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-01-29","conditions":"Heart Transplant","enrollment":66},{"nctId":"NCT04202679","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-01-16","conditions":"Neurodermatitis","enrollment":160},{"nctId":"NCT04183335","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-12","conditions":"Neurodermatitis","enrollment":151},{"nctId":"NCT06488651","phase":"","title":"Trajectory of Immunosuppression-Caused Tremor In Kidney and Lung Transplant Recipients","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2022-08-17","conditions":"Kidney Transplantation, Tremor","enrollment":72},{"nctId":"NCT05646992","phase":"PHASE2, PHASE3","title":"Uterus Transplantation to Treat Infertility","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-01","conditions":"Uterine Factor Infertility","enrollment":40},{"nctId":"NCT06607991","phase":"PHASE1","title":"Blinatumomab for CNI-Resistant/Intolerant SRNS in Children","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-09-19","conditions":"CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent, Steriod Resistant Nephrotic Syndrome","enrollment":6},{"nctId":"NCT05660785","phase":"PHASE2","title":"Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-01","conditions":"Non Severe Aplastic Anemia, Untreated","enrollment":54},{"nctId":"NCT06829719","phase":"NA","title":"TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-23","conditions":"Infection, Cancer, Rejection","enrollment":300},{"nctId":"NCT06880042","phase":"EARLY_PHASE1","title":"COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO","status":"ENROLLING_BY_INVITATION","sponsor":"Dr ayesha wahid","startDate":"2025-05-01","conditions":"Vitiligo - Macular Depigmentation, Tacrolimus","enrollment":60},{"nctId":"NCT04838704","phase":"NA","title":"Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2021-04-01","conditions":"Graft Versus Host Disease","enrollment":215},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT07003438","phase":"EARLY_PHASE1","title":"Study on the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Steroid - Dependent /Steroid-resistant Nephrotic Syndrome in Children","status":"NOT_YET_RECRUITING","sponsor":"Zhang Ting","startDate":"2025-06-01","conditions":"Steroid-Resistant Nephrotic Syndrome, Steroid-Dependent Nephrotic Syndrome","enrollment":120},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT06950931","phase":"","title":"Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital, Martin","startDate":"2024-06-25","conditions":"Transplant Recipient (Kidney), Primary Kidney Transplantation","enrollment":86},{"nctId":"NCT05706636","phase":"NA","title":"T Central Memory Cells in Early Localized Non-Segmental Vitiligo","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-02-01","conditions":"Vitiligo","enrollment":22},{"nctId":"NCT06942156","phase":"PHASE4","title":"Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-08-14","conditions":"Heart Transplant","enrollment":140},{"nctId":"NCT05148715","phase":"PHASE2","title":"Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2022-07-11","conditions":"Organ Transplant Failure or Rejection, Brain Death, Ischemic Reperfusion Injury","enrollment":414},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT03461445","phase":"PHASE4","title":"Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2018-04-01","conditions":"Kidney Transplant; Complications, Toxicity, Drug Toxicity","enrollment":64},{"nctId":"NCT05975450","phase":"PHASE1","title":"Subcutaneous Abatacept in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Idelberto Badell","startDate":"2023-08-02","conditions":"Kidney Transplant Recipient","enrollment":14},{"nctId":"NCT04665310","phase":"PHASE4","title":"Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-09-01","conditions":"Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant","enrollment":46},{"nctId":"NCT04314219","phase":"PHASE3","title":"Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients","status":"RECRUITING","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2021-08-15","conditions":"Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission","enrollment":264},{"nctId":"NCT04469842","phase":"EARLY_PHASE1","title":"Early Use of Long-acting Tacrolimus in Lung Transplant Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-01","conditions":"Lung Transplant; Complications","enrollment":48},{"nctId":"NCT06299462","phase":"PHASE1, PHASE2","title":"PTCy and ATG for MSD and MUD Transplants","status":"RECRUITING","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2024-06-14","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT06676696","phase":"PHASE4","title":"Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","status":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2024-01-22","conditions":"Renal Failure , Chronic, Graft Failure, Graft Rejection","enrollment":202},{"nctId":"NCT01316133","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients","status":"TERMINATED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2011-04-19","conditions":"Lupus Nephritis","enrollment":37},{"nctId":"NCT05459181","phase":"NA","title":"HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)","status":"NOT_YET_RECRUITING","sponsor":"CareDx","startDate":"2025-12","conditions":"Heart Transplant, Immunosuppression, Allograft","enrollment":930},{"nctId":"NCT03413722","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT06493526","phase":"PHASE4","title":"Mycophenolate-Based Therapy for Kidney Transplant Recipients Without HLA-DQ Mismatch","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2024-08-20","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT03832010","phase":"PHASE4","title":"Steroid-reducing Effects of Crisaborole","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-12-17","conditions":"Atopic Dermatitis, Eczema","enrollment":24},{"nctId":"NCT06400771","phase":"PHASE1","title":"Safety of DNP007 in Healthy Subjects","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-06-10","conditions":"Liver Transplant Rejection, Liver Transplant; Complications, Steatohepatitis, Nonalcoholic","enrollment":12},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT06203470","phase":"PHASE4","title":"Botox Versus Tacrolimus in Psoriasis Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-06","conditions":"Psoriasis Vulgaris","enrollment":60},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT05029713","phase":"","title":"Sarcopenic Obesity in Liver Transplanted Patients","status":"COMPLETED","sponsor":"University of Bari","startDate":"2021-05-10","conditions":"Sarcopenic Obesity","enrollment":400},{"nctId":"NCT06406205","phase":"PHASE3","title":"A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-12-25","conditions":"Lupus Nephritis","enrollment":270},{"nctId":"NCT06362720","phase":"","title":"The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen","status":"NOT_YET_RECRUITING","sponsor":"Siriraj Hospital","startDate":"2024-05-01","conditions":"CMV Infection or Reactivation After Allogenic HSCT","enrollment":158},{"nctId":"NCT06279494","phase":"PHASE1, PHASE2","title":"Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-03","conditions":"Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia","enrollment":6},{"nctId":"NCT06307808","phase":"","title":"Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2024-03-15","conditions":"HBV, Kidney Transplantation, Liver Transplantation","enrollment":66},{"nctId":"NCT04559048","phase":"","title":"Investigation of Pain Incidence After FK506 Immunosuppressive Therapy in Liver Transplantation Patients","status":"UNKNOWN","sponsor":"The Second Hospital of Tangshan","startDate":"2019-09-15","conditions":"Chronic Pain, Liver Transplantation","enrollment":300},{"nctId":"NCT05208788","phase":"","title":"Urinary Biomarkers in Paediatric Kidney Transplantation (pKTx)","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2021-06-01","conditions":"Renal Transplantation, Chronic Kidney Insufficiency, Healthy Controls","enrollment":186},{"nctId":"NCT06124885","phase":"NA","title":"Real-time Early Detection of Nephrotoxicity by Urinary Biomarker Analysis With SeroFlow Technology","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2023-11","conditions":"Acute Kidney Injury","enrollment":150},{"nctId":"NCT00685061","phase":"PHASE4","title":"Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2002-11","conditions":"Renal Transplantation","enrollment":90},{"nctId":"NCT05515029","phase":"PHASE3","title":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-08-23","conditions":"Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia","enrollment":56},{"nctId":"NCT04888741","phase":"PHASE2","title":"Methods of T Cell Depletion Trial (MoTD)","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":400},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT04963673","phase":"","title":"Evaluation of Interaction Between Immunosuppressive Drugs and Protein-bound Uremic Toxins in Renal Transplant Patients","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-07-06","conditions":"Kidney Transplant, Immunosuppression, Uremic; Toxemia","enrollment":""},{"nctId":"NCT02533180","phase":"PHASE2","title":"Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-15","conditions":"Liver Transplant, Liver Transplantation","enrollment":100},{"nctId":"NCT00681343","phase":"PHASE4","title":"Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2002-09","conditions":"Living-Donor Kidney Transplant","enrollment":38},{"nctId":"NCT02741323","phase":"PHASE2","title":"Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-01","conditions":"HIV Infections, Kidney Diseases","enrollment":97},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT03864926","phase":"PHASE4","title":"Envarsus in Delayed Graft Function (E-DGF)","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-03-18","conditions":"Delayed Graft Function","enrollment":100},{"nctId":"NCT01686191","phase":"","title":"Genetic Predictors of Renal Dysfunction Following Heart Transplantation","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2012-08","conditions":"Heart Transplantation, Chronic Renal Insufficiency","enrollment":300},{"nctId":"NCT05001074","phase":"PHASE3","title":"Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients","status":"UNKNOWN","sponsor":"Heleen Grootjans","startDate":"2020-07-28","conditions":"Lung Transplant; Complications","enrollment":145},{"nctId":"NCT05423496","phase":"NA","title":"KidneyCare Immuno-optimization in Renal Allografts (KIRA)","status":"WITHDRAWN","sponsor":"CareDx","startDate":"2022-08","conditions":"Kidney Transplant, Immunosuppression, Allograft","enrollment":""},{"nctId":"NCT03021499","phase":"PHASE3","title":"Aurinia Renal Response in Active Lupus With Voclosporin","status":"COMPLETED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2017-05-17","conditions":"Lupus Nephritis","enrollment":358},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT05352880","phase":"NA","title":"Hypomagnesemia and Its Association With Calcineurin Inhibitors Use in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-05-10","conditions":"Renal Transplantation; Complication","enrollment":80},{"nctId":"NCT03597464","phase":"PHASE3","title":"Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin","status":"COMPLETED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2019-09-29","conditions":"Lupus Nephritis","enrollment":216},{"nctId":"NCT02327403","phase":"PHASE2","title":"Belatacept Conversion in Proteinuric Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2015-10","conditions":"Proteinuria","enrollment":15},{"nctId":"NCT01903473","phase":"PHASE2","title":"Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)","status":"TERMINATED","sponsor":"University of Liege","startDate":"2013-07","conditions":"Chronic Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Steroid Refractory Graft-Versus-Host Disease","enrollment":19},{"nctId":"NCT01656343","phase":"","title":"Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10-31","conditions":"Kidney Transplantation, Transplantation, Kidney","enrollment":775},{"nctId":"NCT05421299","phase":"","title":"A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-16","conditions":"Stem Cell Transplantation","enrollment":378},{"nctId":"NCT05375435","phase":"PHASE4","title":"Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"Dermatomyositis, Adult Type, Interstitial Lung Disease","enrollment":120},{"nctId":"NCT01935128","phase":"PHASE4","title":"Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07-03","conditions":"Renal Transplant","enrollment":55}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"CYTOMEGALOVIRUS INFECTION"},{"count":4,"reaction":"DISEASE RECURRENCE"},{"count":3,"reaction":"ACUTE GRAFT VERSUS HOST DISEASE"},{"count":3,"reaction":"ANAEMIA"},{"count":3,"reaction":"ASCITES"},{"count":3,"reaction":"NEUROTOXICITY"},{"count":3,"reaction":"OFF LABEL USE"},{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"ACUTE HEPATIC FAILURE"},{"count":2,"reaction":"BLOOD CREATININE INCREASED"}],"_approvalHistory":[],"publicationCount":4895,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tacrolimus (Prograf)","Cyclosporine (Gengraf)","Mycophenolic Acid (Myfortic)","Prograf, Tacrolimus, Cyclosporine","Tacrolimus, Cyclosporin, NeoOral, Prograf"],"phase":"marketed","status":"active","brandName":"Calcineurin Inhibitor","genericName":"Calcineurin Inhibitor","companyName":"Milton S. Hershey Medical Center","companyId":"milton-s-hershey-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcineurin inhibitors block the phosphatase enzyme calcineurin, preventing T cell activation and proliferation by inhibiting the transcription of pro-inflammatory cytokines. Used for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (e.g., atopic dermatitis, psoriasis, rheumatoid arthritis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}